{"filing":{"accession_number":"0001824293-26-000050","cik":"0001824293","ticker":"GRI","company_name":"GRI Bio, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"val-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000050/val-20260618.htm"},"events":[{"id":11949,"run_id":10515,"accession_number":"0001824293-26-000050","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"GRI Bio announced FDA Orphan Drug Designation (ODD) for GRI-0621 in idiopathic pulmonary fibrosis, a significant regulatory milestone that provides potential seven-year U.S. market exclusivity, tax credits, and enhanced FDA engagement. While this is a material regulatory achievement for a clinical-stage biotech company, it does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M\u0026A activity, impairment, or litigation). The ODD is a positive regulatory catalyst that would affect investor assessment of the company's development pathway and long-term value creation.","company_name":"GRI Bio, Inc.","ticker":"GRI","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8669,"accession_number":"0001824293-26-000050","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"GRI Bio announced FDA Orphan Drug Designation (ODD) for GRI-0621 in idiopathic pulmonary fibrosis, a significant regulatory milestone that provides potential seven-year U.S. market exclusivity, tax credits, and enhanced FDA engagement. While this is a material regulatory achievement for a clinical-stage biotech company, it does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M\u0026A activity, impairment, or litigation). The ODD is a positive regulatory catalyst that would affect investor assessment of the company's development pathway and long-term value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:52:06.838842+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8669,"accession_number":"0001824293-26-000050","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"GRI Bio announced FDA Orphan Drug Designation (ODD) for GRI-0621 in idiopathic pulmonary fibrosis, a significant regulatory milestone that provides potential seven-year U.S. market exclusivity, tax credits, and enhanced FDA engagement. While this is a material regulatory achievement for a clinical-stage biotech company, it does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M\u0026A activity, impairment, or litigation). The ODD is a positive regulatory catalyst that would affect investor assessment of the company's development pathway and long-term value creation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:52:06.838842+00:00","company_name":"GRI Bio, Inc.","ticker":"GRI","filing_date":"2026-06-18"}]}